BioNTech SE (BNTX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    BioNTech SE

    NASDAQ: BNTX · Real-Time Price · USD
    112.46
    8.96 (8.66%)
    At close: Sep 05, 2025, 3:59 PM
    112.01
    -0.40%
    After-hours: Sep 05, 2025, 07:09 PM EDT

    BioNTech SE Income Statement

    Financials in EUR. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 2.75B 3.82B 17.31B 18.98B
    Cost of Revenue
    		 541.3M 599.8M 4.53B 3.86B
    Gross Profit
    		 2.21B 3.22B 12.78B 15.12B
    Operating Income
    		 -1.31B 690.4M 12.64B 15.28B
    Interest Income
    		 437.6M 350.27M 48.5M 1.56M
    Pretax Income
    		 -677.7M 1.19B 12.95B 15.05B
    Net Income
    		 -665.3M 930.3M 9.43B 10.29B
    Selling & General & Admin
    		 599M 557.7M 544.2M 328.9M
    Research & Development
    		 2.25B 1.78B 1.46B 952.85M
    Other Expenses
    		 670.9M 188M -408.3M -128.8M
    Operating Expenses
    		 3.52B 2.53B 135.9M 200.1M
    Interest Expense
    		 12.6M 569.94K 18.9M 5.62M
    Selling & Marketing Expenses
    		 67.9M 62.7M 59.5M 50.4M
    Cost & Expenses
    		 4.07B 3.13B 4.67B 4.06B
    Income Tax Expense
    		 -12.4M 255.8M 3.52B 4.75B
    Shares Outstanding (Basic)
    		 240.4M 240.6M 243.3M 244M
    Shares Outstanding (Diluted)
    		 240.4M 242.7M 249.8M 259.7M
    EPS (Basic)
    		 -2.77 3.87 38.08 43.87
    EPS (Diluted)
    		 -2.77 3.83 37.09 41.21
    EBITDA
    		 -367.1M 1.09B 12.86B 15.73B
    EBIT
    		 -665.1M 1.19B 12.74B 15.65B
    Depreciation & Amortization
    		 298M 183.4M 121.08M 78.2M

    Add to Watchlist